Transaction · 0001810417-26-000023

Sullivan Christopher Ryan

Sullivan Christopher Ryan, CFO, reported an open-market or private sale at Avalo Therapeutics, Inc. involving 12394.000000 shares for an estimated $202437.40. Reported holdings after the transaction were 39900.000000 shares. The stored filing text includes a detected 10b5-1 reference.

Open-market sellSEC transaction code SCFO
AVTXAvalo Therapeutics, Inc.
Trade date
Sep 16, 2026
Filing date
Sep 18, 2026
View on SEC Insider profile
Estimated value-$202kShares × reported price
Shares traded12.3k$16.33 per share
Holdings after39.9kDirect
% of reported position traded23.7%This security and ownership context
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 52,294 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

AVTX price since this filing

Daily closing prices, with the filing date and available return windows
AVTX · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +20.4%1w ago +9.9%1d ago -3.0%
Returns since7d -6.6%30d -32.0%90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0001810417-26-000023
Common Stock
Transaction date
Sep 16, 2026
Filed Sep 18, 2026, 08:10 PM · 2d delay
Shares
12,394 sh
$16.33 per share
Estimated value
-$202k
Computed from shares × price
Holdings after
39,900 sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Direct Ownership Large Holdings Reduction Repeat Seller 10b5-1 Detected
Filing-only score

0 points

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

How this score is calculated
  • direct_ownership+6 points

    direct_or_indirect_ownership = D

    Direct ownership reports the insider's personal stake.
  • timely_filing+4 points

    reporting_delay_days = 2

    Filing reported within two business days of the transaction.
  • tenb5_1_detected-10 points

    is_10b5_1 = true

    Stored filing content includes detected 10b5-1 language.
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

Chief Financial Officer

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2026.

  2. F2

    The reported securities were sold in multiple transactions at prices ranging from $15.91 to $16.65. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the s…

  3. F3

    The stock option vests 25% on March 28, 2025, and 1/36 monthly thereafter, subject to the Reporting Person's continued service on such vesting date.

Original filing · 0001810417-26-000023
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

AVTX